Prokidney Corp. (PROK) Stock Forecast Oct. 15, 2026
Analysis updated on Oct. 15, 2026 (UTC) · Alpha · vs marketSwitch to Total · Nasdaq
Prokidney Corp. (PROK) stock forecast summary
Our AI ranks Prokidney Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
Prokidney Corp. is a small-cap company with a market capitalization of $442M. It ranks number 60 by market capitalization among the 60 Biological Products, (No Diagnostic Substances) issuers in our coverage with a current forecast.
For PROK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
Expected return relative to the market over the horizon: a positive alpha means the model expects the stock to beat the market, whatever the market does. Ratings: strong buy ≥ +1.3%, buy ≥ +0.2%, sell < -0.9%, strong sell < -1.5% (top 15%, next 20%, middle 30%, next 20%, bottom 15% of the 2026-10-15 signals)
A free account shows the exact forecast, rating and rank of 3 tickers you follow, PROK included.
Follow PROK freePROK price chart and AI forecast
How PROK ranks among 5111 stocks
90D Alpha forecasts of every company scored, cut into five relative ratings at the 15th, 35th, 65th and 85th percentiles (dashed lines).
Prokidney Corp. (PROK) fundamentals
Trailing twelve months. The industry median and the rank (1 = highest) are taken over the Biological Products, (No Diagnostic Substances) peers listed below that report each metric.
Valuation & Market
| Metric | PROK | Rank |
|---|---|---|
| Market Cap | $442M | 60/60 |
| Revenue/Share | $0.00 | – |
| FCF/Share | $-0.53 | – |
Profitability & Margins
| Metric | PROK | Rank |
|---|---|---|
| Tax Rate | 0.6% | – |
Financial Health
| Metric | PROK | Rank |
|---|---|---|
| Current Ratio | 8.36x | 21/59 |
| Interest Coverage | -2995.5x | 34/39 |
| Working Capital | $167M | 51/59 |
Cash Flow
| Metric | PROK | Rank |
|---|---|---|
| Operating Cash Flow | -$141M | 32/57 |
| Free Cash Flow | -$160M | 30/49 |
| Capital Spending | -$19M | 35/49 |
| FCF/Sales | -19527.4% | 31/31 |
| CapEx/Sales | 2269.8% | 1/31 |
Operational Efficiency
| Metric | PROK | Rank |
|---|---|---|
| Fixed Assets Turnover | 0.0x | 35/36 |
Income Statement
| Metric | PROK | Rank |
|---|---|---|
| Total Revenue | $820K | 35/36 |
| Operating Income | -$177M | 27/54 |
| Net Income | -$98M | 22/52 |
| R&D Expense | $131M | 37/56 |
Dividend & Shareholder Information
| Metric | PROK | Rank |
|---|---|---|
| Shares Outstanding | 301M | – |
Balance Sheet Highlights (USD millions)
| Total Current Assets | $190M | |
| Cash & Short-term Investments | $75M | |
| Total Liabilities | $13M | |
| Short-term Debt | $21M |
PROK quarterly financials and insider trading
Prokidney Corp. (PROK) industry peers
Companies classified under the same SEC industry code as Prokidney Corp. (Biological Products, (No Diagnostic Substances)): 60 common-stock issuers with a forecast this week, one row per issuer, largest first. This is a classification match, not a curated list of competitors.
Reveal all forecasts · See exact % predictions for all competitors
Sign up free| Company | 90-Day AI Forecast (Alpha) | Market Cap |
|---|---|---|
| PROK Prokidney Corp. | ▲ | $442M |
| AMGN Amgen Inc | ▼ | $230.37B |
| GILD Gilead Sciences, Inc. | ▲ | $190.38B |
| MRNA Moderna, Inc. | ▲ | $90.35B |
| ARGX Argenx Se | ▼ | $50.64B |
| RVMD Revolution Medicines, Inc. | ▲ | $41.48B |
| BIIB Biogen Inc. | ▼ | $34.16B |
| BNTX Biontech Se | ▲ | $22.42B |
| EXEL Exelixis, Inc. | ▶ | $15.11B |
| NBIX Neurocrine Biosciences Inc | ▲ | $13.82B |
| HALO Halozyme Therapeutics, Inc. | ▶ | $13.26B |
| TECH Bio-Techne Corp | ▼ | $11.37B |
| IBRX Immunitybio, Inc. | ▲ | $10.50B |
| RGEN Repligen Corp | ▶ | $10.06B |
| PCVX Vaxcyte, Inc. | ▲ | $10.05B |
| QGEN Qiagen N.V. | ▶ | $9.88B |
| KRYS Krystal Biotech, Inc. | ▶ | $9.79B |
| TWST Twist Bioscience Corp | ▲ | $9.29B |
| KYMR Kymera Therapeutics, Inc. | ▲ | $8.88B |
| IOVA Iovance Biotherapeutics, Inc. | ▲ | $6.44B |
| IMVT Immunovant, Inc. | ▲ | $5.76B |
| CGON Cg Oncology, Inc. | ▲ | $5.48B |
| KOD Kodiak Sciences Inc. | ▲ | $5.10B |
| CRSP Crispr Therapeutics Ag | ▲ | $4.86B |
| SRRK Scholar Rock Holding Corp | ▲ | $4.82B |
| ADPT Adaptive Biotechnologies Corp | ▲ | $4.08B |
| RLAY Relay Therapeutics, Inc. | ▲ | $3.74B |
| TARS Tarsus Pharmaceuticals, Inc. | ▲ | $3.17B |
| DNLI Denali Therapeutics Inc. | ▼ | $2.86B |
| LIFE Atyr Pharma Inc | ▲ | $2.46B |
| BEAM Beam Therapeutics Inc. | ▲ | $2.44B |
| ADMA Adma Biologics, Inc. | ▼ | $2.40B |
| RXRX Recursion Pharmaceuticals, Inc. | ▲ | $2.25B |
| NVAX Novavax Inc | ▲ | $2.08B |
| VCEL Vericel Corp | ▲ | $2.06B |
| BCRX Biocryst Pharmaceuticals Inc | ▲ | $2.06B |
| ALVO Alvotech | ▲ | $1.85B |
| MESO Mesoblast Ltd | ▶ | $1.77B |
| VIR Vir Biotechnology, Inc. | ▲ | $1.76B |
| IMCR Immunocore Holdings Plc | ▶ | $1.46B |
| MAZE Maze Therapeutics, Inc. | ▲ | $1.46B |
| COAG Hemab Therapeutics Holdings, Inc. | ▼ | $1.40B |
| SCNI Scinai Immunotherapeutics Ltd. | ▶ | $1.22B |
| TSHA Taysha Gene Therapies, Inc. | ▲ | $1.14B |
| VOR Vor Biopharma Inc. | ▶ | $1.11B |
| REPL Replimune Group, Inc. | ▲ | $1.07B |
| JATT Zura Bio Ltd | ▶ | $994M |
| VALN Valneva Se | ▼ | $965M |
| IMTX Immatics N.V. | ▲ | $938M |
| MGTX Meiragtx Holdings Plc | ▶ | $904M |
| CGEM Cullinan Therapeutics, Inc. | ▲ | $878M |
| GLUE Monte Rosa Therapeutics, Inc. | ▲ | $839M |
| ODTX Odyssey Therapeutics, Inc. | ▲ | $798M |
| DNA Ginkgo Bioworks Holdings, Inc. | ▲ | $776M |
| SANA Sana Biotechnology, Inc. | ▲ | $698M |
| CADL Candel Therapeutics, Inc. | ▲ | $694M |
| FDMT 4d Molecular Therapeutics, Inc. | ▲ | $674M |
| AURA Aura Biosciences, Inc. | ▲ | $640M |
| SLDB Solid Biosciences Inc. | ▲ | $586M |
| PRME Prime Medicine, Inc. | ▲ | $568M |
Where PROK sits on the market map
Prokidney Corp. (PROK) stock news
Loading...
Prokidney Corp. (PROK) stock forecast FAQ
What is the Prokidney Corp. (PROK) stock forecast?
Our AI ranks Prokidney Corp. outside the neutral middle of its coverage (a directional signal). Create a free account and follow it to see the exact price target.
How accurate are Prokidney Corp. stock predictions?
For PROK, the Spearman rank correlation between our 90-day forecasts and the returns that followed is 0.0%, measured on 358 forecast dates between 2022-07-28 and 2026-07-17 on this stock's own recent history. A rank correlation runs from -100% to +100%: it measures whether higher forecasts were followed by higher returns, and a value near zero or below means the model has shown little skill on this stock. On the 30-day forecasts the same correlation is -1.0%, measured on 400 forecast dates between 2022-07-28 and 2026-09-15. Across our coverage, the out-of-sample test on 4495 stocks from 2025-01-06 to 2026-07-07 produced a positive net return in 82.5% of rebalance periods (factor-neutral book, net of estimated costs). Full backtest report
How often are Prokidney Corp. forecasts updated?
Prokidney Corp. forecasts are refreshed on trading days as the daily model run completes. The forecast on this page was produced on Oct. 15, 2026.
Which companies are Prokidney Corp.'s industry peers?
60 issuers in our coverage, PROK included, share the SEC industry code Biological Products, (No Diagnostic Substances). The largest are: Amgen Inc (AMGN), Gilead Sciences, Inc. (GILD), Moderna, Inc. (MRNA), Argenx Se (ARGX), Revolution Medicines, Inc. (RVMD), Biogen Inc. (BIIB).
This analysis is generated automatically using our proprietary AI systems and should not be considered personalized investment advice. Past performance does not guarantee future results. Always conduct your own research and consider consulting a financial advisor before making investment decisions.